My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.
My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of Pennsylvania
Post Frank A, Tebas Pablo, Clarke Amanda, Cotte Laurent, Short William, Abram Michael E, Jiang Shuping, Cheng Andrew, Das Moupali, Fordyce Marshall W: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. Journal of acquired immune deficiency syndromes (1999) Sep 2016.
Lederman MM, Cannon PM, Currier JS, June CH, Kiem HP, Kuritzkes DR, Lewin SR, Margolis DM, McCune JM, Mellors JW, Schacker TW, Sekaly RP, Tebas P, Walker BD, Douek DC: A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"? Pathogens & immunity 1(1): 154-164, September 2016.
Jacobson JM, Bosinger SE, Kang M, Belaunzaran-Zamudio P, Matining RM, Wilson CC, Flexner C, Clagett B, Plants J, Read S, Purdue L, Myers L, Boone L, Tebas P, Kumar P, Clifford D, Douek D, Silvestri G, Landay AL, Lederman MM: The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. AIDS Research and Human Retrovirus 32(7): 636-47, Jul 2016.
Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Callebaut C, Das M, Fordyce M, GS-US-2,92-01040111 and Study Team: Brief Report: A Randomized, Double-Blind comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil fumarate (TDF), each coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for initial HIV-1 Treatment: Week 96 results. J Acquir Immune Defic Syndr 72(1): 58-64, May 2016.
Overton ET, Tebas P, Coate B, Ryan R, Perniciaro A, Dayaram YK, De La Rosa G, Baugh BP: Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. HIV clinical trials 17(2): 72-7, Mar 2016.
Jacobson JM, Zheng L, Wilson CC, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N, Actg A Protocol Team: The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. J Acquir Immune Defic Syndr 71(2): 163-71, February 2016.
Bedimo R, Cutrell J, Zhang S, Drechsler H, Gao A, Brown G, Farukhi I, Castanon R, Tebas P, Maalouf NM: Mechanisms of bone disease in HIV and hepatitis C virus: impact of bone turnover, tenofovir exposure, sex steroids and severity of liver disease. AIDS 30(4): 601-8, February 2016.
Gowda C, McKittrick N, Kim D, Kappes RA, Lo Re V 3rd, Tebas P: Obesity Is Not Associated with Impaired Immune Response to Influenza Vaccination in HIV-Infected Persons. AIDS Res Treat 2015: 653840, December 2015.
Bedimo, R., Kang, M., Tebas, P., Overton, E. T., Hollabaugh, K., McComsey, G., Bhattacharya, D., Evans, C., Brown, T. T., Taiwo, B.: Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients. AIDS Res Hum Retroviruses November 2015.
Tebas P, Kumar P, Hicks C, Granier C, Wynne B, Min S, Pappa K: Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS Septemeber 2015.
back to top
Last updated: 03/07/2017
The Trustees of the University of Pennsylvania